Lora Hamuro

7PUBLICATIONS
17CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Radiation therapyAdolescent health
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|May 20, 2026
HLA Class II Alleles DRB1*11:01 and DQB1*03:01 Unmask Immunogenetic Susceptibility to Anti-Nivolumab Antibodies in Combination with Ipilimumab.

|Aug 18, 2025
Exposure-Response Analysis of Repotrectinib to Support the Dose Recommendation for Patients With ROS1-Positive NSCLC or NTRK-Positive Solid Tumors.

Shengnan Du, Zheyi Hu, Jun Shen

|May 02, 2025
A Novel Empirical Autoinduction Model to Characterize the Population Pharmacokinetics and Recommend Dose for Repotrectinib in Adult and Adolescents With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements.

Shengnan Du, Zheyi Hu, Jun Shen

|Apr 25, 2025
Model-Informed Immunogenicity Assessment of Nivolumab as Monotherapy and in Combination with Ipilimumab.

Yue Zhao, Li Li, Jessica Ma

|Oct 24, 2023
Pediatric model-based dose optimization using a pooled exposure-response safety analysis for nivolumab and nivolumab plus ipilimumab combination in melanoma.

Shengnan Du, Yue Zhao, Zheyi Hu

|Jan 04, 2022
Exposure-Response Analysis to Support Nivolumab Once Every 4 Weeks Dosing in Combination with Cabozantinib in Renal Cell Carcinoma.

Lora Hamuro, Zheyi Hu, Julie Passarell

Pageof 2

Frequent Collaborators

3 joint publications

Shengnan Du

3 joint publications

Jun Shen

2 joint publications

Amit Roy

2 joint publications

Ming Lu